Product Description
Mechanisms of Action: B2 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Xytis Pharmaceuticals SÃ rl
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Traumatic Brain Injury
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2006-002813-11 |
BRAIN trial | P2 |
Terminated |
Traumatic Brain Injury |
2008-07-02 |
2022-03-12 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|